Лучшие доктора по лечению лимфомы в Китае – ТОП-7 докторов

Профессор Ху Кай руководить исследованиями лимфомы, проведя более 20 клинических испытаний. Он возглавляет Пекинский экспертный комитет по опухолям крови.

• 21 год специализируется в области гематологии и онкологии
• Выполнил более 900 процедур по лечению рака крови
• Является пионером в области иммунотерапии и исследований биомаркеров
• Возглавляет Пекинский комитет по диагностике опухолей крови
• Является членом Рабочей группы по Т-клеточной лимфоме Китая

Dr. Lu Peihua is a U.S. and China-licensed hematology and oncology expert and a pioneer in cell immunotherapy. After graduating from Beijing Medical University, she trained in the U.S. and completed a clinical fellowship at Stanford University, later receiving two prestigious NIH awards. She was among the first to introduce Cytokine-Induced Killer (CIK) cell therapy in China. Since returning to China in 2015, she has led advancements in CAR-T therapy and hematologic cancer treatment. Dr. Lu holds leadership roles in more than 10 medical organizations, including Chair of the Hematology Committee under the Chinese Non-Public Medical Institutions Association. She has been honored with national awards such as the "Medical Management Award" and "People's Doctor of the Year."
 

Department: General Hematology, Lymphoma&Myeloma Center

Dr. Lu Yue is a senior transplant specialist at Lu Daopei Hospital with over 1,800 allogeneic stem cell transplants completed by the end of

2024. He graduated from Xiangya Hospital, Central South University in

2004 and has worked with the Lu Daopei Medical Group since then. In

2016, he trained at the Fred Hutchinson Cancer Research Center in Seattle. He has published more than 10 SCl papers in journals such as Frontiers in Immunology and British Journal of Haematology, and holds roles in major hematology societies including the Beijing Hematology Association and the Chinese Society of Hematology.
 

Department: Hematopoietic Stem Cell Transplantation

Dr. Zhao Yanli is a medical doctor with over 20 years of experience in hematology and stem cell transplantation, having completed more than 1,500 allogeneic transplants. She trained at MD Anderson Cancer Center in 2011 and specializes in haploidentical, unrelated, sibling-matched, and cord blood transplantation. She has extensive expertise in treating complex conditions such as elderly AML, MDS/MPN, CMML, and post-immunotherapy bridging transplants. Dr. Zhao is skilled in personalized approaches for rare diseases like HLH, NK/T-cell lymphoma, and PNH.

Her research has been presented at ASH, EBMT, and APBMT, and she serves as a committee member in various hematology and cancer societies across Beijing and Hebei.
 

Department: Hematopoietic Stem Cell Transplantation

Dr. Cao Xingyu, PhD graduate from Xiangya Medical School, has led the transplant unit at Lu Daopei Hospital since 2004 and has performed over 1,400 stem cell transplants by March 2025. He is an expert in treating both malignant and rare inherited blood disorders, including AML, ALL, HLH, Fanconi anemia, and Bruton's disease. His clinical strengths include second and third transplants, CAR-T bridging, and long-term survival post-transplant (up to 14 years). He trained at Mayo Clinic and has published in top journals such as AJH, BJH, and Frontiers in Immunology. Dr. Cao is a core contributor to national transplant guidelines and an active speaker at major international conferences like ASH and EHA.

Department: Hematopoietic Stem Cell Transplantation

Biography

Dr. Zhou Daobin is a chief physician and doctoral advisor, formerly Head of Hematology at Peking Union Medical College Hospital. He specializes in hematologic malignancies and stem cell transplantation. Dr. Zhou has served as Chairman of the Beijing Hematology Association, Vice President of the Chinese Medical Doctor Association Hematology Branch, and is a standing member in multiple national academic committees. He is also an editorial board member for key journals such as Chinese Journal of Hematology and Clinical Hematology Journal.
 

Department: Lymphoma & Myeloma Center